Egenix Licenses Harvard University Anti-Cancer Platform

MILLBROOK, N.Y., Jan. 31 /PRNewswire/ -- Mr. Donald Fresne, Chairman and CEO of Egenix, Inc., announced today that the company has recently obtained from Harvard University a field-exclusive license under patent rights that cover certain technologies related to cancer therapy and prognostic testing. The licensed technologies, which were developed jointly by scientists in the Laboratory for Translational Research and the Department of Biological Chemistry and Molecular Pharmacology, each of Harvard Medical School, comprise small molecule inhibitors of translation initiation, a new paradigm in target- specific, non-cytotoxic anti-cancer therapy, and the use of translation initiation-specific biomarkers to assess tumor sensitivity to anti-cancer therapy with this novel class of anti-cancer drugs. Specifically, the inhibitors of translation initiation licensed by Egenix from Harvard Medical School target the eIF4F and ternary complexes, the two critical regulators of messenger RNA translation into protein.

The company's management believes that small molecules for the inhibition of translation initiation are at the forefront of modern cancer therapeutics currently under development and that this cutting-edge platform has the potential to yield significant breakthroughs in the biomedical field for the treatment of cancer.

About Egenix, Inc.

Based in Millbrook, New York, Egenix, Inc. is a privately held biotechnology company responding to the demand for more effective cancer therapies.

Terms and conditions of the license agreement are not disclosed.

CONTACT: Donald Fresne of Egenix, Inc., +1-845-677-5317

Web site: http://www.egenixinc.com/